Lab Saphire
Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site.
More than Meets the Eye: Hidden Structures in the Proteome.
A “Trojan horse” bispecific-antibody strategy for broad protection against ebolaviruses.
Analytical Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection.
Structures of Ebola virus GP and sGP in complex with therapeutic antibodies.
How to turn competitors into collaborators.
Crystal Structure of the Marburg Virus VP35 Oligomerization Domain.
The Ebola Virus VP30-NP Interaction Is a Regulator of Viral RNA Synthesis.
Filovirus Structural Biology: The Molecules in the Machine.
Structural basis for antibody-mediated neutralization of Lassa virus.
Oxidation-sensitive polymersomes as vaccine nanocarriers enhance humoral responses against Lassa virus envelope glycoprotein.
Role of Non-local Interactions between CDR Loops in Binding Affinity of MR78 Antibody to Marburg Virus Glycoprotein.
The Marburgvirus-Neutralizing Human Monoclonal Antibody MR191 Targets a Conserved Site to Block Virus Receptor Binding.
A cationic, C-terminal patch and structural rearrangements in Ebola virus matrix VP40 protein control its interactions with phosphatidylserine.
Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region.
Antibodies to the Glycoprotein GP2 Subunit Cross-React between Old and New World Arenaviruses.
Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever.
Antibody Repertoires to the Same Ebola Vaccine Antigen Are Differentially Affected by Vaccine Vectors.
Pan-Filovirus Serum Neutralizing Antibodies in a Subset of Congolese Ebolavirus Infection Survivors.
Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection.
A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus.
Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein.
The structural basis for filovirus neutralization by monoclonal antibodies.
Lassa virus glycoprotein: stopping a moving target.
Structural Basis of Pan-Ebolavirus Neutralization by a Human Antibody against a Conserved, yet Cryptic Epitope.
Structural Characterization of Pan-Ebolavirus Antibody 6D6 Targeting the Fusion Peptide of the Surface Glycoprotein.
In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse Model.
Antibody-mediated protection against Ebola virus.
Early human B cell response to Ebola virus in four U.S. survivors of infection.
Cross-reactive neutraliing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk
A Conserved Basic Patch and Central Kink in the Nipah Virus Phosphoprotein Multimerization Domain Are Essential for Polymerase Function.
Longitudinal analysis of the human B cell response to ebola virus infection
Diverse morphology and structural features of old and new world hantaviruses
Convergent structures illuminate features for germline antibody binding and pan-Lassa virus neutralization
Antibody therapy for Lassa fever
Sudan ebolavirus VP35-NP crystal structure reveals a potential target for pan-filovirus treatment
SARS-CoV-2 Omicron (B.1.1.529) shows minimal neurotropism in a double-humanized mouse model
Reporter Assays for Ebola Virus Nucleoprotein Oligomerization, Virion-Like Particle Budding, and Minigenome Activity Reveal the Importance of Nucleoprotein Amino Acid Position 111
A Vaccine against Ebola Virus
Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization
Evidence for distinct mechanisms of small molecule inhibitors of filovirus entry
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
Analysis of oligomeric and glycosylated proteins by size-exclusion chromatography coupled with multiangle light scattering.
Structural biology in the fight against COVID-19.
Lifted Up from Lockdown
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Evidence for distinct mechanisms of small molecule inhibitors of filovirus entry.
Prominent neutralizing antibody response targeting the ebolavirus glycoprotein subunit interface elicited by immunization.
Cellular mRNA triggers structural transformation of Ebola virus matrix protein VP40 to its essential regulatory form.
A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus.
An intranasal vaccine durably protects against SARS-CoV-2 variants in mice.
Proteo-genomic analysis identifies two major sites of vulnerability on ebolavirus glycoprotein for neutralizing antibodies in convalescent human plasma.
Ebola vaccine-induced protection in non-human primates correlates with antibody specificity and Fc-mediated effects.
Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: a global consortium study.
Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination.
SARS-CoV-2 infection generates tissue-localized immunological memory in humans.
Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large scale synthetic phage libraries.
Novel attempts launched toward universal sarbecovirus vaccine.
CD164 is a host factor for lymphocytic choriomeningitis virus entry
Pan-ebolavirus serology study of healthcare workers in the Mbandaka Health Region, Democratic Republic of the Congo
mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern
Functional interactomes of the Ebola virus polymerase identifed by proximity proteomics in the context of viral replication
Development and Structural Analysis of Antibody Therapeutics for Filoviruses
Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses
Stopping pandemics before they start: Lessons learned from SARS-CoV-2
Measles and Nipah virus assembly: Specific lipid binding drives matrix polymerization
Structure of the rabies virus glycoprotein trimer bound to a prefusion-specific neutralizing antibody
Delineating the mechanism of anti-Lassa virus GPC-A neutralizing antibodies
mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions
Inducing broad-based immunity against viruses with pandemic potential
Neutralizing Antibodies against Lassa Virus Lineage I
Glycan shield of the ebolavirus envelope glycoprotein GP
A circular MRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera.
Proximity interactome analysis of Lassa polymerase reveals eRF3a/GSPT1 as a druggable target for host-directed antivirals
A cocktail of protective antibodies subverts the dense glycan shield of Lassa virus
IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern
Lessons from the pandemic: Responding to emerging zoonotic viral diseases-a Keystone Symposia report
Coronavirus Immunotherapeutic Consortium Database
Structure if the Inmazeb cocktail and resistance to Ebola virus escape
Structural basis for antibody-mediated neutralization of lymphocytic choriomeningitis virus
Bivalent intra-spike binding provides durability against emergent Omicron lineages: Results from a global consortium
Spatial and functional arrangement of Ebola virus polymerase inside phase-separated viral factories
ChAdOx1 nCoV-19(AZD1222) vaccine-induced Fc receptor bindingtracks with differential susceptibilityto COVID-19
The in situ Structural Approach to Reveal the Filovirus Budding Mechanism
B cell and antibody targeting of transplant alloantigen epitopes is supported by both self and allo-recognition
Potent Omicron-neutralizing antibodies isolated from a patient vaccinated 6 months before Omicron emergence
A Lassa virus mRNA vaccine confers protection but does not require neutralizing antibody in a guinea pig model of infection
The C-terminus of Sudan ebolavirus VP40 contains a functionally important CXnC motif, a target for redox modifications
Identification of mouse CD4+ T cell epitopes in SARS-CoV-2 BA.1 spike and nucleocapsid for use in peptide:MHCII tetramers
Aerosol Delivery of SARS-CoV-2 human monoclonal antibodies in macaques limits viral replication and lung pathology
The Arenaviridae Family: Knowledge Gaps, Animal Models, Countermeasures, and Prototype Pathogens
Structure of a SARS-CoV-2 spike S2 subunit in a pre-fusion, open conformation
The evolution and determinants of neutralization of potent head-binding antibodies against Ebola virus
LJI scientists win ‘Prebys Research Heroes’ funding
Prebys Foundation celebrates ground-breaking female researchers
Erica Ollmann Saphire wins 2023 Pantheon Award from California Life Sciences
LJI President and CEO celebrated among California’s leading life sciences innovators
LJI joins national effort to prevent pandemics by harnessing the fascinating science of x-ray crystallography
With new funding, LJI scientists will help lay the groundwork for faster vaccine and therapeutic development
A new look inside Ebola’s ‘viral factories’
LJI researchers reveal a hidden side of how Ebola virus replicates inside host cells
Virologist Onyeka Chukwudozie wins support for international collaboration
New Merkin Fellowship to support U.K. collaboration on Lassa virus research
Even as SARS-CoV-2 mutates, some human antibodies fight back
A 'cocktail' of human antibodies shows promise in fighting severe SARS-CoV-2 infections
